Vertex Pharms. Inc. v. Lupin Ltd.

Start
Case Name: Vertex Pharms. Inc. v. Lupin Ltd., No. 22-cv-966-SB, 2026 WL 2474714 (D. Del. Aug. 24, 2026) (Bibas, J.)  Drug Product and Patent(s)-in-Suit: Kalydeco® (ivacaftor); U.S. Patent Nos. 10,646,481 (“the ’481 patent”), 11,564,916 (“the ’916 patent”), 12,458,635 (“the ’635 patent”), and 10,272,046 (“the ’046 patent”)…
By: Robins Kaplan LLP
Previous Story

The Cybersecurity Reality Check: Ten Myths That Matter

Next Story

UPC upholds pharmaceutical patent for subgroup of patients: Key lessons for patent holders and challengers